Ken Griffin Ionis Pharmaceuticals Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$40.06 - $51.86 $624,936 - $809,016	-15,600 Reduced 28.26%	39,600 $1.59 Million
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $626,940 - $820,440	17,200 Added 45.26%	55,200 $2.63 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $764,946 - $974,610	18,200 Added 91.92%	38,000 $1.65 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $512,002 - $609,234	11,800 Added 147.5%	19,800 $1 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $365,750 - $447,735	-9,500 Reduced 54.29%	8,000 $362,000
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $736,275 - $918,596	-21,200 Reduced 54.78%	17,500 $718,000
Q1 2023 May 15, 2023	BUY	$33.58 - $41.2 $520,490 - $638,600	15,500 Added 66.81%	38,700 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $81,664 - $102,344	2,200 Added 10.48%	23,200 $876,000
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $43,848 - $58,391	1,200 Added 6.06%	21,000 $929,000

402

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.06B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.